Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 206 results

Notice of Special Interest (NOSI): Stimulate Research on the Diagnosis, Treatment, and Mechanistic Understanding of Postural Orthostatic Tachycardia Syndrome (POTS)

Notice of Special Interest
Friday, March 26, 2021
Wednesday, May 8, 2024
R01
NOT-HL-21-008

Funding Opportunity Purpose

Individuals with Postural Orthostatic Tachycardia Syndrome (POTS) suffer from an excessive increase in heart rate (tachycardia) and other symptoms that worsen upon standing or sitting up, such as light-headedness, shortness of breath, chest pain, and palpitations. It is likely that POTS has multiple underlying mechanisms resulting in subtypes of POTS that need to be identified and characterized. There is evidence that POTS can arise from abnormalities in autonomic nervous system function, immune system function including autoimmunity, regulation of blood volume and blood flow, or a combination of these factors. Genetic factors probably also affect susceptibility to POTS. Many people with POTS report a preceding medical or life-changing event such as viral infection, concussion, surgery, pregnancy, or puberty. Due to the highly variable symptoms and signs of POTS across different people, it is likely that POTS is best defined as a syndrome with several subtypes that have distinct underlying causes.

Neural Mechanisms of Force-Based Manipulations: High Priority Research Networks (U24 Clinical Trial Optional)

RFA
Tuesday, March 23, 2021
Thursday, July 15, 2021
U24
RFA-AT-21-006

Funding Opportunity Purpose

This proposed initiative aims to solicit applications that focus on developing resources by refining and testing key concepts that will advance and further support the study of the neurocircuitry of force-based manipulations. This grant funding initiative will support research networks through meetings, conferences, small-scale pilot research, multidisciplinary cross training (such as intensive workshops, summer institutes, or visiting scholar programs), and information dissemination to foster the growth and development of research in the specified priority areas listed below.

Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)

RFA
Tuesday, March 23, 2021
Wednesday, August 25, 2021
R01
RFA-MD-21-004

Funding Opportunity Purpose

This initiative will support (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities.

Notice of Special Interest (NOSI) to add harassment as an area of interest to Research to Understand and Inform Interventions that Promote the Research Careers of Individuals in the Biomedical Sciences

Notice of Special Interest
Thursday, March 18, 2021
Saturday, January 8, 2022
R01
NOT-OD-21-068

Funding Opportunity Purpose

The purpose of this Notice is to inform potential applicants of the NIHs interest in supporting research on interventions designed to change the culture to mitigate or eliminate sexual harassment in the biomedical research enterprise. This notice aligns with the Anti-Sexual Harassment policy notice released by NIH as well as recommendations made in the December 2019 Report from the Working Group to the Advisory Committee to the NIH Director on Changing the Culture to End Sexual Harassment.

Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)

PAR
Thursday, March 18, 2021
Monday, January 8, 2024
PAR-21-173

Funding Opportunity Purpose

SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher education institutions that receive limited NIH research support and serve students from groups underrepresented in biomedical research (see NOT-OD-20-031) with an emphasis on providing students with research opportunities and enriching the research environments at the applicant institutions. The purpose of SuRE-First awards is to support research grants for faculty investigators at eligible institutions who have not had prior independent external research grants.

Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)

PAR
Thursday, March 18, 2021
Friday, September 8, 2023
PAR-21-169

Funding Opportunity Purpose

SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher education institutions that receive limited NIH research support and serve students from groups underrepresented in biomedical research NOT-OD-20-031 with an emphasis on providing students with research opportunities and enriching the research environment at the applicant institutions. ?The purpose of SuRE awards is to provide research grant support for faculty investigators at eligible institutions who haveprior experience in leading externally-funded, independent research butare not currently funded by any NIH Research Project Grants with the exception of SuRE or SuRE-First awards.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

PAR
Friday, March 12, 2021
Wednesday, February 21, 2024
R61/R33
PAR-21-123

Funding Opportunity Purpose

This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

PAR
Friday, March 12, 2021
Translational Research
Wednesday, February 21, 2024
R61/R33
PAR-21-124
Rebecca A. Roof

Funding Opportunity Purpose

This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

PAR
Friday, March 12, 2021
Translational Research
Wednesday, February 21, 2024
R61/R33
PAR-21-122
Rebecca A. Roof

Funding Opportunity Purpose

This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

PAR
Thursday, March 11, 2021
Wednesday, May 8, 2024
UG3/UH3
PAR-21-163

Funding Opportunity Purpose

The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

Pages